For instance, in NSCLC patients with acquired resistance to anti-PD-1/PD-L1 immunotherapies and EGFR or ALK mutations, particularly for patients with high tumor burden or rapid disease progression, a combination of anti-PD-1/PD-L1 therapy and targeted therapy may be an option. Here, CD274 is linked to neoplasm.